

## Azithromycin

Section	Indications
<p>Watch group antibiotics</p> <p>Oral &gt; Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid</p> <p>Oral &gt; Solid &gt; dosage form: 250 mg (anhydrous); 500 mg (anhydrous)</p>	<p><b>First choice</b></p> <p>Chlamydia trachomatis</p> <p>Typhoid fever</p> <p>Yaws</p> <p>Paratyphoid fever</p> <p>Cholera</p> <p>Cholera [children]</p> <p>Trachoma</p> <p>co-prescribed with ceftriaxone</p> <p>Gonococcal infection</p> <p><b>Second choice</b></p> <p>Infectious gastroenteritis or colitis without specification of infectious agent</p> <p>co-prescribed with cefixime</p> <p>Gonococcal infection</p>

## Cefepime

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral &gt; General injections &gt; unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection</p>	<p>Other specified bacterial diseases</p>

## Cefixime

Section	Indications
<p>Watch group antibiotics</p> <p>Oral &gt; Liquid: 100 mg per 5 mL powder for oral liquid</p> <p>Oral &gt; Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)</p>	<p><b>Second choice</b></p> <p>Infectious gastroenteritis or colitis without specification of infectious agent</p> <p>co-prescribed with azithromycin</p> <p>Gonococcal infection</p>

# Cefotaxime

## Section

### Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

## Indications

### First choice

Other specified pneumonia (Hospital-acquired pneumonia)

Bacterial meningitis

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with amikacin

Inflammatory and other diseases of prostate (severe)

co-prescribed with amikacin

Acute pyelonephritis (severe)

co-prescribed with clarithromycin

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescribed with metronidazole

Peritonitis (severe)

co-prescribed with metronidazole

Peritonitis (mild-moderate)

co-prescribed with metronidazole

Peritoneal abscess (severe)

co-prescribed with metronidazole

Peritoneal abscess (mild-moderate)

### Second choice

Osteomyelitis or osteitis

Bacterial infection of joint

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

Sepsis without septic shock

### Other indications

Bacterial infection of unspecified site

## Ceftazidime

### Section

#### Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

### Indications

#### First choice

co-prescribed with [vancomycin](#)

[Endophthalmitis](#)

#### Other indications

[Pseudomonas aeruginosa resistant to other antibiotic](#)

## Ceftriaxone

### Section

#### Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 2 g in vial; 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

### Indications

#### First choice

[Typhoid fever](#)

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#)

[Paratyphoid fever](#)

[Other specified pneumonia \(Hospital-acquired pneumonia\)](#)

[Bacterial meningitis](#)

co-prescribed with [amikacin](#)

[Acute pyelonephritis \(severe\)](#)

co-prescribed with [amikacin](#)

[Inflammatory and other diseases of prostate \(severe\)](#)

co-prescribed with [azithromycin](#)

[Gonococcal infection](#)

co-prescribed with [clarithromycin](#)

[Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

co-prescribed with [metronidazole](#)

[Necrotising fasciitis](#)

co-prescribed with [metronidazole](#)

[Peritonitis \(mild-moderate\)](#)

co-prescribed with [metronidazole](#)

[Peritonitis \(severe\)](#)

co-prescribed with [metronidazole](#)

[Peritoneal abscess \(mild-moderate\)](#)

co-prescribed with [metronidazole](#)

[Peritoneal abscess \(severe\)](#)

co-prescribed with [vancomycin](#)

Endophthalmitis

Second choice

Bacterial infection of joint

Osteomyelitis or osteitis

Infectious gastroenteritis or colitis without specification of infectious agent

Sepsis without septic shock

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

Other indications

Bacterial infection of unspecified site

## Cefuroxime

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

Indications

Second choice

Other specified prophylactic measures

## Ciprofloxacin

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 2 mg per mL (as hyclate)

Oral > Liquid: 250 mg per 5 mL (anhydrous)

Oral > Solid: 250 mg (as hydrochloride)

Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)

Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

### Indications

#### First choice

Neutropenia (low-risk)

Inflammatory and other diseases of prostate (mild to moderate)

Typhoid fever

Paratyphoid fever

Infectious gastroenteritis or colitis without specification of infectious agent

Acute pyelonephritis (mild to moderate)

#### Second choice

Cholera

Cholera [children]

co-prescribed with metronidazole

Peritoneal abscess (mild-moderate)

co-prescribed with metronidazole

Peritonitis (mild-moderate)

#### Other indications

Bacterial infection of unspecified site

## Clarithromycin

### Section

#### Watch group antibiotics

Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid

Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Oral > Solid > dosage form: 500 mg; 250 mg

Oral > Solid > dosage form: 500 mg

### Indications

#### First choice

co-prescribed with cefotaxime

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescribed with ceftriaxone

Bacterial pneumonia (Community-acquired pneumonia - severe)

#### Second choice

Acute pharyngitis

co-prescribed with amoxicillin + clavulanic acid

Bacterial pneumonia (Community-acquired pneumonia - severe)

#### Other indications

Helicobacter pylori associated gastric ulcer

## Delafloxacin

### Section

Watch group antibiotics

Parenteral > General injections > IV: 300 mg lyophilized powder for injection

Oral > Solid: 450 mg

### Indications

Methicillin resistant *Staphylococcus aureus*

## Erythromycin

### Section

Watch group antibiotics

Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)

Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)

Oral > Solid: 250 mg (as stearate or ethylsuccinate)

### Indications

#### Second choice

Therapeutic equivalent to *clarithromycin* for

Acute pharyngitis

#### Other indications

Bacterial infection of unspecified site

## Flomoxef

### Section

Watch group antibiotics

Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection

### Indications

Other specified other antibiotic resistant *Enterobacterales*

## Fourth generation cephalosporins

### Section

Watch group antibiotics

.

### Indications

Other specified bacterial diseases

## Imipenem + cilastatin

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

### Indications

#### Second choice

Therapeutic equivalent to meropenem for

Neutropenia (high-risk)

Therapeutic equivalent to meropenem for

Peritoneal abscess (severe)

Therapeutic equivalent to meropenem for

Peritonitis (severe)

#### Other indications

Pseudomonas aeruginosa resistant to other antibiotic

Antibiotic resistant Acinetobacter baumannii

## Meropenem

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

### Indications

#### Second choice

Neutropenia (high-risk)

Peritoneal abscess (severe)

Peritonitis (severe)

Neonatal meningitis

## Piperacillin + tazobactam

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

### Indications

#### First choice

Peritoneal abscess (severe)

Other specified pneumonia (Hospital-acquired pneumonia)

Neutropenia (high-risk)

Peritonitis (severe)

co-prescribed with clindamycin

Necrotising fasciitis

## Vancomycin

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection

Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)

Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

### Indications

#### First choice

Necrotising fasciitis

co-prescribed with [ceftazidime](#)

Endophthalmitis

co-prescribed with [ceftriaxone](#)

Endophthalmitis

#### Second choice

Neutropenia (high-risk)

Intestinal infections due to *Clostridioides difficile*

#### Other indications

Methicillin resistant *Staphylococcus aureus*